Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Cervical cancer in 2013

Screening comes of age and treatment progress continues

Nature Reviews Clinical Oncology volume 11, pages 77–78 (2014)Cite this article

Subjects

In 2013, studies confirmed that HPV infection of target cells predisposes to cervical (pre)cancer. In developed countries, HPV screening revealed superior protection than cytology screening. In India, visual inspection of the cervix after acetic acid application significantly reduced cervical cancer mortality after 12 years. Improved survival for women with advanced disease was observed after adjuvant bevacizumab.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Herfs, M. et al. Cervical squamocolumnar junction-specific markers define distinct, clinically relevant subsets of low-grade squamous intraepithelial lesions. Am. J. Surg. Pathol. 37, 1311–1318 (2013).

    Article  Google Scholar 

  2. Herfs, M. et al. A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc. Natl Acad. Sci. USA 109, 10516–10521 (2012).

    Article  CAS  Google Scholar 

  3. Ronco, G. et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet http://dx.doi.org/10.1016/S0140-6736(13)62218-7 (2013).

  4. Arbyn, M. et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30 (Suppl. 5), F88–F99 (2012).

    Article  Google Scholar 

  5. Rijkaart, D. C. et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 13, 78–88 (2012).

    Article  Google Scholar 

  6. Ronco, G. et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 11, 249–257 (2010).

    Article  CAS  Google Scholar 

  7. Shastri, S. S. et al. Effect of visual inspection with acetic acid (VIA) screening by primary health workers on cervical cancer mortality: a cluster randomized controlled trial in Mumbai, India [abstract]. J. Clin. Oncol. 31 (Suppl.), a2 (2013).

    Article  Google Scholar 

  8. Tewari, K. S. et al. Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group [abstract]. J. Clin. Oncol. 31 (Suppl.), a3 (2013).

    Article  Google Scholar 

  9. Kirk, R. From ASCO—Gynaecological cancer: advances in cervical cancer screening and treatment. Nat. Rev. Clin. Oncol. 10, 425 (2013).

    Article  Google Scholar 

Download references

Acknowledgements

This work has been made possible by grants from the European Union: FP7 frame work programme agreement no242061 PREHDICT, and agreement no: 603019 COHEAHR.

Author information

Authors and Affiliations

  1. Department of Pathology, Vrije Universiteit Medical Centre Amsterdam, de Boelelaan 1117, Amsterdam, 1084 HV, The Netherlands

    Chris J. L. M. Meijer & Peter J. F. Snijders

Authors
  1. Chris J. L. M. Meijer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter J. F. Snijders
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chris J. L. M. Meijer.

Ethics declarations

Competing interests

C. J. L. M. Meijer and P. J. F. Snijders have minority stock in self-screen, a spin-off company of the Vrije Universiteit in Amsterdam. C. J. L. M. Meijer has been member of the scientific Advisory board of Qiagen and has been occasionally on the Advisory board of GlaxoSmithKline and Roche. P. J. F. Snijders has been occasionally on the Advisory Board of Roche, GlaxoSmithKline and Genprobe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meijer, C., Snijders, P. Screening comes of age and treatment progress continues. Nat Rev Clin Oncol 11, 77–78 (2014). https://doi.org/10.1038/nrclinonc.2013.252

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2013.252

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer